K932208 is an FDA 510(k) clearance for the EXTRACORPOREAL CIRCUIT W/DURAFLO II HEPARIN TREATM. Classified as Catheter, Cannula And Tubing, Vascular, Cardiopulmonary Bypass (product code DWF), Class II - Special Controls.
Submitted by Baxter Healthcare Corp (Irvine, US). The FDA issued a Cleared decision on August 9, 1994 after a review of 460 days - an unusually long review period, suggesting complex equivalence evaluation.
This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.4210 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Cardiovascular submissions.
View all Baxter Healthcare Corp devices